Overview

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Antibodies, Monoclonal
Carboplatin
Cisplatin
Etoposide
Etoposide phosphate